GE Reports
FDA Approves New Imaging Agent for Detection of Beta Amyloid
Alzheimer's disease (AD) is the sixth leading cause of death in the United States, the fifth-leading cause of death for individuals age 65 and older and it has no cure. The U.S. Food and Drug Administration (FDA) just approved a new brain imaging agent for use in the detection of beta amyloid plaques in adult patients with cognitive impairment who are being evaluated for AD or other causes of cognitive decline as an adjunct to other diagnostic evaluations. Read More: www.gereports.com/fda-approves-new-imaging-agent/
FDA Approves New Imaging Agent for Detection of Beta Amyloid
Alzheimer's disease (AD) is the sixth leading cause of death in the United States, the fifth-leading cause of death for individuals age 65 and older and it has no cure. The U.S. Food and Drug Administration (FDA) just approved a new brain imaging agent for use in the detection of beta amyloid plaques in adult patients with cognitive impairment who are being evaluated for AD or other causes of cognitive decline as an adjunct to other diagnostic evaluations. Read More: www.gereports.com/fda-approves-new-imaging-agent/